Lupin Revises Timeline for VISUfarma Acquisition; Completion Expected by February 2026

Lupin Limited has announced an update regarding its proposed acquisition of **VISUfarma B.V., Netherlands**, extending the expected completion timeline of the transaction. Earlier, the company had indicated that the acquisition would be finalized by the end of calendar year 2025. However, as per the latest disclosure, the deal is now **expected to close by February 28, 2026**, subject to the fulfillment of certain closing conditions. The acquisition is being undertaken through **Nanomi B.V.**, a wholly owned subsidiary of Lupin. VISUfarma, headquartered in Amsterdam, is a specialty pharmaceutical company with a strong presence in ophthalmology and niche therapeutic segments across Europe. The transaction aligns with Lupin’s broader strategy to deepen its footprint in **specialty and complex pharmaceutical markets**, particularly in regulated geographies. The timeline extension appears procedural in nature and does not indicate any change in the transaction’s structure, strategic intent, or commercial terms. Delays of this nature are not uncommon in cross-border acquisitions, often arising from regulatory approvals, legal processes, or final documentation. From an investor standpoint, the update suggests **continuity rather than concern**, with Lupin reaffirming its commitment to the acquisition. The successful completion of the VISUfarma deal could support Lupin’s long-term growth ambitions and enhance its European specialty portfolio. **Disclaimer:** This article is for informational purposes only and does not constitute investment advice. Investors should consult certified financial advisors before taking investment decisions. 👉 *Follow for timely corporate updates and market-focused insights.*